These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35537933)

  • 1. Expert recommendations for the use of apremilast in psoriatic arthritis.
    Torre Alonso JC; Almodóvar González R; Montilla Morales C; Sanz Sanz J; Díaz González F; Pascual Alfonso E; Gratacós J
    Reumatol Clin (Engl Ed); 2023 Jan; 19(1):34-44. PubMed ID: 35537933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
    Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA).
    Lapadula G; Marchesoni A; Salaffi F; Ramonda R; Salvarani C; Punzi L; Costa L; Caso F; Simone D; Baiocchi G; Scioscia C; Di Carlo M; Scarpa R; Ferraccioli G
    Reumatismo; 2016 Dec; 68(3):126-136. PubMed ID: 27981814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
    Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
    Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Apremilast in Psoriasis: A Delphi Study.
    Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies and resources to optimise the management of Psoriatic Arthritis patients: The CREA Project.
    Almodóvar R; Cañete JD; Collantes E; de Miguel E; Fernández Carballido C; Gratacós J; Juanola X; Pinto JA; Queiro R; Zarco P
    Reumatol Clin (Engl Ed); 2023 Mar; 19(3):159-167. PubMed ID: 36068162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
    Gladman DD; Kavanaugh A; Gómez-Reino JJ; Wollenhaupt J; Cutolo M; Schett G; Lespessailles E; Guerette B; Delev N; Teng L; Edwards CJ; Birbara CA; Mease PJ
    RMD Open; 2018; 4(1):e000669. PubMed ID: 30018799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
    de Vlam K; Toukap AN; Kaiser MJ; Vanhoof J; Remans P; Van den Berghe M; Di Romana S; Van den Bosch F; Lories R
    Adv Ther; 2022 Feb; 39(2):1055-1067. PubMed ID: 34977986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast and its role in psoriatic arthritis.
    Sandhu VK; Eder L; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Med Clin (Barc); 2022 Jul; 159(1):40-46. PubMed ID: 35525675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
    Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
    Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.